KalVista Pharmaceuticals trades as part of the biotechnology industry and trades as part of the healthcare sector. KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.



Previous Intraday Performance:

The KALV shares had a previous change of -1.97% which opened at 20.06 and closed at 19.41. It moved to an intraday high of 20.09 and a low of 18.77.

Business Wire:  KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology

Historical Performance:

Over the last five trading days, KALV shares returned -16.01% and in the past 30 trading days it returned -25.26%. Over three months, it changed -14.87%. In one year it has changed 136.42% and within that year its 52 week high was 34.92 and its 52 week low was 7.73. KALV stock is 151.10% above its 52 week low.

Our calculations result in a 200 day moving average of 21.12 and a 50 day moving average of 25.07. Right now, KALV stock is trading -8.12% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

Business Wire:  KalVista Pharmaceuticals Presents KVD900 Data at European Academy of Allergy and Clinical Immunology

Liquidity:

The company has a market cap of $334.8m with 17.2m shares outstanding and a float of 16.8m shares. Trading volume was 150,884 shares and has experienced an average volume of 135,288 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for KalVista Pharmaceuticals was -1.54 which ended on 30th of April 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.27.

Below was the last reported quarterly diluted earnings per share:

Jan19Reported 03-14-2019: -0.23
Oct18Reported 12-14-2018: -0.22
Jul18Reported 09-14-2018: -0.47
Apr18Reported 07-31-2018: -0.06
Jan18Reported 03-16-2018: -0.49

The next earnings report will be: 06-13-2019

The growth of the EPS is critical in understanding the current valuation of KalVista Pharmaceuticals; it is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 295.40% over the last twelve months.



Indicators Also to Watch:

Based on the latest filings, there is 89.60% of institutional ownership.

The beta was calculated to be 2.20.

SeekingAlpha:  Microcaps tops midday movers

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -13.78%, profit margin is -93.10%, price-to-sales is 25.87 and price-to-book is 3.28.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here